Wolfe Research on Ionis Pharmaceuticals (IONS): new Tryngolza pricing likely to ‘squeeze’ Arrowhead’s rival drug
Tweet Send to a Friend
Wolfe Research analyst Andy Chen reiterated an Outperform rating and $97.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
